Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

IONOS Aktie 124525998 / DE000A3E00M1

11.11.2025 07:31:13

EQS-News: IONOS reports successful first nine months of 2025 – AdTech business to be sold

EQS-News: IONOS Group SE / Key word(s): 9 Month figures/Interim Report
IONOS reports successful first nine months of 2025 – AdTech business to be sold

11.11.2025 / 07:31 CET/CEST
The issuer is solely responsible for the content of this announcement.


 
  • + 210,000 customers to 6.53 million
  • + 6.2% revenue to €980.2 million
  • + 20.8% adjusted EBITDA to €368.5 million
  • + 40.6% adjusted earnings per share to €1.35
  • AdTech business put up for sale
  

Karlsruhe / Berlin, 11 November 2025. IONOS Group SE looks back on a successful first nine months of 2025. Revenue, EBITDA, and customer numbers continued to increase.

The Management Board of IONOS Group SE has decided to put Sedo GmbH, and thus the “AdTech” segment, up for sale and to focus entirely on the core business areas of “Web Presence & Productivity” and “Cloud Solutions.”

The AdTech business unit, which is not part of IONOS's core business, has increasingly developed from a secondary market for the use and trading of domains into a platform for traffic monetization. This repositioning opens up numerous opportunities for the AdTech business unit, but these must be developed with the appropriate focus.

With the decision to put the “AdTech” segment up for sale, the division is reported separately as a discontinued operation in accordance with IFRS 5. The financial figures for the previous year have been adjusted accordingly.

 

Business development

The IONOS customer base grew by around 210,000 to 6.53 million customers in the first nine months of 2025 (December 31, 2024: 6.32 million customers).

Revenue (previously “Digital Solutions & Cloud” segment) increased by 6.2% to €980.2 million (comparable prior-year figure for 9M 2024: €923.1 million) or by 6.6% excluding intercompany revenue. Adjusted EBITDA rose by 20.8% to €368.5 million (comparable prior-year figure for 9M 2024: €305.1 million). The adjusted EBITDA margin improved accordingly to 37.6% (9M 2024: 33.0%).

Adjusted earnings per share (EPS) rose by 40.6% to €1.35 (9M 2024: €0.96).

"The AdTech business faces exciting challenges and at the same time has a lot of potential. To leverage this potential, increasing management attention is required, which we cannot provide optimally on a permanent basis. In the future, we want to focus entirely on our core business,“ said Achim Weiss, CEO of IONOS Group SE. ”The development of AI, from conversational AI to reasoning to autonomous AI and multi-agent AI systems, is heralding a new era. With the launch of IONOS Momentum, we are bundling our existing AI products and will be rolling out a variety of products and enhancements in the coming months. IONOS Momentum makes AI accessible and easy to use for every entrepreneur.“

 

Forecast

The company confirms its forecast, which previously referred to its remaining core business, ”Digital Solutions & Cloud". Adjusted for currency effects, revenue is expected to grow by approximately 8% in fiscal year 2025 (2024: €1,248.1 million), with an adjusted EBITDA margin of approximately 35% (2024: 32.9%). Adjusted EBITDA in the remaining core business is expected to increase by approximately 17% to approximately €480 million (2024: €410.4 million).

 

Media contact:
Andreas Maurer
press@ionos-group.com
Phone +49 721 50957968
 

Investor Relations contact:
Stephan Gramkow
investor-relations@ionos-group.com
Phone +49 721 50957097


11.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: IONOS Group SE
Elgendorfer Strasse 57
56410 Montabaur
Germany
E-mail: info@ionos-group.com
ISIN: DE000A3E00M1
WKN: A3E00M
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 2227258

 
End of News EQS News Service

2227258  11.11.2025 CET/CEST

Analysen zu IONOS

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
09:53 IONOS Overweight JP Morgan Chase & Co.
30.10.25 IONOS Buy Deutsche Bank AG
20.10.25 IONOS Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
15.09.25 IONOS Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
15.08.25 IONOS Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’119.73 19.77 BDGS0U
Short 13’385.87 13.84 NTUBSU
Short 13’884.77 8.90 UJ3S8U
SMI-Kurs: 12’689.95 11.11.2025 16:34:28
Long 12’102.65 19.77 S0CB8U
Long 11’840.64 13.99 S3JBXU
Long 11’345.90 8.99 BEFSQU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

IONOS 24.63 -9.93% IONOS